ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-CDH6 Antibody-drug Conjugate SIM0505

Its studies are mostly in Fallopian Tube Neoplasms, led by NextCure.

Furthest: phase 1, since Jan 13, 20251 company-led study, 1 open or runningNext primary completion: Feb 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
NextCure11 open or runningphase 1since Jan 13, 2025Jan 13, 2025Feb 2028phase 1 · NCT06792552

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 13, 2025First study: phase 1 study in Fallopian Tube NeoplasmsFirst studyNCT06792552 · 738 planned · United States, China

Ahead

  1. Feb 2028Primary completion: phase 1 study in Fallopian Tube NeoplasmsNCT06792552

TargetBeta

CDH6 →read by rule
“An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) cadherin-6 (CDH6; CDH-6; K-cadherin) ”NCIt, by rule

Other programs on CDH6

ProgramCompanyFurthest phaseStudies
raludotatug deruxtecanMerckphase 311
TJ102rulephrontline-biopharmaphase 21

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06792552Fallopian Tube Neoplasms · United States, China1RecruitingFeb 2028738

How it is read

Names in the registry

  • “SIM0505 for injection”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.